D Orazio & Associates Inc. Has $1.55 Million Holdings in DexCom, Inc. $DXCM

D Orazio & Associates Inc. grew its position in DexCom, Inc. (NASDAQ:DXCM) by 17.1% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 17,779 shares of the medical device company’s stock after purchasing an additional 2,599 shares during the quarter. D Orazio & Associates Inc.’s holdings in DexCom were worth $1,552,000 as of its most recent SEC filing.

A number of other large investors also recently made changes to their positions in the company. Nuveen LLC bought a new stake in DexCom in the 1st quarter valued at $554,893,000. Jennison Associates LLC boosted its position in shares of DexCom by 37.7% in the first quarter. Jennison Associates LLC now owns 10,523,246 shares of the medical device company’s stock valued at $718,632,000 after acquiring an additional 2,879,489 shares during the period. Massachusetts Financial Services Co. MA grew its stake in shares of DexCom by 171.0% in the first quarter. Massachusetts Financial Services Co. MA now owns 3,194,829 shares of the medical device company’s stock valued at $218,175,000 after acquiring an additional 2,015,971 shares in the last quarter. Federated Hermes Inc. increased its position in DexCom by 2,371.4% during the first quarter. Federated Hermes Inc. now owns 1,994,732 shares of the medical device company’s stock worth $136,220,000 after acquiring an additional 1,914,019 shares during the period. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in DexCom by 22.6% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 10,123,525 shares of the medical device company’s stock worth $691,336,000 after purchasing an additional 1,868,241 shares in the last quarter. Institutional investors own 97.75% of the company’s stock.

DexCom Trading Up 2.5%

Shares of DXCM opened at $59.61 on Thursday. DexCom, Inc. has a 52-week low of $54.11 and a 52-week high of $93.25. The business’s fifty day moving average is $68.12 and its 200-day moving average is $77.39. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.35 and a current ratio of 1.52. The firm has a market cap of $23.25 billion, a price-to-earnings ratio of 41.40, a PEG ratio of 1.43 and a beta of 1.40.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings data on Thursday, October 30th. The medical device company reported $0.61 earnings per share for the quarter, topping the consensus estimate of $0.57 by $0.04. The business had revenue of $1.21 billion during the quarter, compared to the consensus estimate of $1.18 billion. DexCom had a return on equity of 30.41% and a net margin of 13.29%.DexCom’s revenue for the quarter was up 21.6% on a year-over-year basis. During the same period in the prior year, the company earned $0.45 EPS. DexCom has set its FY 2025 guidance at EPS. Equities analysts anticipate that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

Insider Buying and Selling

In other DexCom news, Director Bridgette P. Heller sold 1,012 shares of the firm’s stock in a transaction that occurred on Wednesday, November 12th. The shares were sold at an average price of $58.07, for a total value of $58,766.84. Following the sale, the director owned 27,031 shares in the company, valued at $1,569,690.17. This trade represents a 3.61% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, COO Jacob Steven Leach bought 18,200 shares of the firm’s stock in a transaction on Monday, November 10th. The shares were bought at an average cost of $55.04 per share, for a total transaction of $1,001,728.00. Following the purchase, the chief operating officer owned 331,697 shares of the company’s stock, valued at approximately $18,256,602.88. The trade was a 5.81% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders sold a total of 10,343 shares of company stock worth $710,852 in the last quarter. Corporate insiders own 0.32% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on the stock. Raymond James Financial increased their target price on shares of DexCom from $99.00 to $102.00 and gave the stock a “strong-buy” rating in a research report on Thursday, July 31st. William Blair upgraded DexCom to a “strong-buy” rating in a research note on Thursday, July 31st. Sanford C. Bernstein restated an “outperform” rating and set a $84.00 price objective on shares of DexCom in a research note on Monday, November 3rd. BTIG Research dropped their price objective on DexCom from $109.00 to $85.00 and set a “buy” rating for the company in a report on Friday, October 31st. Finally, Cowen reissued a “buy” rating on shares of DexCom in a report on Friday, October 24th. Three equities research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $87.62.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.